Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus
Conclusions Empagliflozin combined with other oral treatments decreased HbA1c, body weight, and SBP/DBP as compared to placebo, with a good safety and tolerability profile.
Source: Endocrinologia y Nutricion - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | Jardiance | Metformin | Nutrition | Urinary Tract Infections